Neuromyelitis optica (NMO): acute treatment
Evidence-based neurology checklist on neuromyelitis optica (nmo): acute treatment: Steroids Methylprednisolone Then followed by oral steroids for 2-6 months Plasma exchange (PE) Treatment of tonic spasms Predictors of poor response to treatment
Steroids
- Methylprednisolone
- Then followed by oral steroids for 2-6 months
Plasma exchange (PE)
Treatment of tonic spasms
Predictors of poor response to treatment
References
- Argyriou AA, Makris N. Neuromyelitis optica: a distinct demyelinating disease of the central nervous system. Acta Neurol Scand 2008; 128:209-217.
- Palace J, Leite I, Jacob A. A practical guide to the treatment of neuromyelitis optica. Pract Neurol 2012; 12:209-214.
- Scott TF, Frohman EM, De Seze J, Gronseth GS, Weinshenker BG. Evidence-based guideline: clinical exaltation and treatment of transverse myelitis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011; 77:2128-2134.
- Bonnan M, Valentino R, Debeugny S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. JNNP 2018; 89:346-351.
- Jiao Y, Cui L, Zhang W, et al. Plasma exchange for neuromyelitis optica spectrum disorders in chinese patients and factors predictive of short-term outcome. Clin Ther 2018; 40:603-612.
- And 3 more. Subscribe to see the full list
Related checklists
- Neuromyelitis optica (NMO): cranial radiological features
- Neuromyelitis optica (NMO): spinal radiological features
- Neuromyelitis optica (NMO): differentials of LETM
- Neuromyelitis optica (NMO): radiological differential from MS
- Neuromyelitis optica (NMO): antibodies
- Neuromyelitis optica (NMO): CSF analysis
- Neuromyelitis optica (NMO): other investigations
- Neuromyelitis optica (NMO): long-term immunosuppression treatment